"Poly (ADP-ribose) Polymerase Inhibitors(PARPi) in the Management of Ovarian Cancer"
This information comes from
-
"Familial and hereditary factors have been identified in the development of some cases of ovarian cancer, with approximately 10% to 15% of ovarian cancer cases associated with inherited mutations of the BRCA1 and BRCA2 genes.
Upon recurrence of disease, the goal of treatment is no longer curative, but instead becomes palliative, aimed at improving disease-related symptoms, prolonging survival, and trying to improve quality of life.
For patients harbouring a BRCA1/2 mutation, medications targeting PARP enzymes may be an effective therapeutic option. PARP is a family of enzymes that mediate DNA repair... PARP inhibition in the setting of BRCA1/2 mutations can cause tumour cells to lose 2 important DNA repair mechanisms leading to DNA damage and cell death.
-
PARPi is administered as maintenance therapy (with) some patients deriving durable benefit for more than 3 years
Australian scientists (using the Melbourne tissue bank) have revealed a better way to identify which patients should respond to powerful ovarian cancer drugs called PARP inhibitors (PARPi), resolving an important question in ovarian cancer care about why some patients respond to these drugs, while others do not.
was led by Professor Clare Scott, Dr Olga Kondrashova, Dr Matthew Wakefield and Dr Monique Topp from the Walter and Eliza Hall Institute; in collaboration with Associate Professor Alexander Dobrovic from the Olivia Newton-John Cancer Research Institute and LaTrobe University School of Medicine".
(L-R) DR OLGA KONDRASHOVA AND PROFESSOR CLARE SCOTT
No comments:
Post a Comment